DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Phase 4

Not yet recruiting

Conditions: Uveitis

Interventions: Drug: Adalimumab plus different doses of oral glucocorticosteroid

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 130

Registration Number: NCT05105347

25G and 22G Puncture Needles

Conditions: Submucosal Tumor
Pancreas Tumor

First Posted Date: 2021-11-01

Last Posted Date: 2021-11-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 73

Registration Number: NCT05101772

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

Characterizing LAM With 11C-Choline PET/CT

Early Phase 1

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: 11C-Choline

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 50

Registration Number: NCT05087134

Locations: 🇨🇳
Peking union medical college hospital, Beijing, Dongcheng, China

Telitacicept in Primary APS Patients

Phase 2

Conditions: Anti Phospholipid Syndrome

Interventions: Drug: Telitacicept

First Posted Date: 2021-10-14

Last Posted Date: 2021-10-14

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT05078710

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Multiomics-based Prediction Model for GDM

Conditions: GDM

First Posted Date: 2021-10-14

Last Posted Date: 2021-10-14

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT05078697

Locations: 🇨🇳
Department of ob gyn , Peking Union Medical College Hospital, Beijing, Beijing, China

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Neuroendocrine Carcinoma

Interventions: Drug: Chidamide
Drug: Etoposide + Cisplatin/Carboplatin

First Posted Date: 2021-10-13

Last Posted Date: 2021-11-03

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 28

Registration Number: NCT05076786

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Phase 3

Recruiting

Conditions: T-cell Lymphoma

Interventions: Drug: Tucidinostat, Azacitidine combined with CHOP

First Posted Date: 2021-10-12

Last Posted Date: 2024-04-09

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 107

Registration Number: NCT05075460

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Early Phase 1

Recruiting

Conditions: Neuroendocrine Tumor
Pheochromocytoma
Paraganglioma
Neuroblastoma

Interventions: Drug: 18F-MFBG
Drug: 68Ga-Dotatate

First Posted Date: 2021-10-06

Last Posted Date: 2024-03-01

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 150

Registration Number: NCT05069220

Locations: 🇨🇳
Peking union medical college hospital, Beijing, Dongcheng, China

Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL

Phase 3

Recruiting

Conditions: Diffuse Large B Cell Lymphoma
Central Nervous System Lymphoma

Interventions: Drug: Methotrexate

First Posted Date: 2021-09-23

Last Posted Date: 2021-09-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 488

Registration Number: NCT05054426

Locations: 🇨🇳
Peking union medical college hospital, Beijing, Beijing, China

Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes

Not Applicable

Recruiting

Conditions: Postoperative Infection
Antibiotics
Lactate

Interventions: Drug: Preventive use of advanced antibiotics
Other: Routine

First Posted Date: 2021-09-22

Last Posted Date: 2021-09-27

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 297

Registration Number: NCT05052619

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy